17 stories mentioning AMGN
Every FINWIRES story that references AMGN, newest first.
Amgen (AMGN) has an average rating of overweight and mean price target of $356.59, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $352.73, Change: $-2.47, Percent Change: -0.70%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price from $398 to $380, based on 16.4x our 2027 EPS estimate, above AMGN's 10-year historical forward average of 14.1x. We cut our 2026 EPS view to $22.45 from $22.56. We keep our 2027 EPS at $23.23. Based on various media reports, AMGN's rare disease drug Tavneos, used to treat ANCA-associated vasculitis in adults, an autoimmune condition where the immune system attacks small blood vessels, has been allegedly linked to 20 deaths in Japan since 2022. On April 27, the U.S. FDA proposed withdrawing the drug's approval, which was granted in 2021, due to concerns over its safety profile and initially disclosed study data. With $119M in global sales in Q1 2026, Tavneos made a very small portion (1.4%) of AMGN's quarterly revenue of $8.62B. Therefore, should AMGN decide to withdraw the drug from the market, we think the financial impact would be manageable. Tavneos entered AMGN's portfolio via the $3.7B acquisition of ChemoCentryx in 2022.
(Updates with response from a Amgen spokesperson in the fourth, fifth and sixth paragraphs.)Amgen's (AMGN) Tavneos kidney disease drug is under heightened scrutiny in Japan, the treatment's local distributor Kissei Pharmaceutical said in a regulatory filing Friday."While the approval of this drug in Japan remains in effect, Kissei has begun providing information to healthcare professionals, urging them to refrain from using this drug for new patients and to carefully assess the continuation of treatment for existing patients, explaining the risks of liver dysfunction and alternative treatments to ensure patient safety," Kissei said.Japan's Asahi Shimbun reported Monday that 20 individuals who took the drug have died in Japan, a number that includes cases in which no causal relationship has been established."Kissei is responsible for and holds rights to TAVNEOS in Japan," an Amgen spokesperson said In a statement emailed to.The spokesperson added that those rights were sold nearly a decade ago, before Amgen or its predecessor company obtained rights to the medicine in other markets."Amgen has never held commercial rights in Japan and does not have operational responsibility there, including relationships with Japanese regulators, clinicians, or the local commercial market," the company said.Price: $322.81, Change: $-3.50, Percent Change: -1.07%
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.4%.The iShares Biotechnology ETF (IBB) rose 1.6%.In corporate news, Sanofi (SNY) said Monday it will invest 294 million Canadian dollars ($216 million) to expand its global AI Centre of Excellence in Toronto in a bid to accelerate the development and delivery of medicines. Its shares were down past 5%.Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Eli Lilly (LLY) shares added 0.7% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Vanda Pharmaceuticals (VNDA) shares jumped past 7% after it said Monday its motion sickness drug Nereus is now commercially available in the US.
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.
Health care stocks declined Monday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) rose 1.2%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down nearly 2%.
Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico.The Juncos site makes biologic medicines distributed to over 60 countries, the company said.Amgen said that over the past year, it announced planned investments of $650 million in Puerto Rico, $900 million in Ohio, as well as $600 million in a facility in California. Amgen said it has also invested over $1.5 billion in North Carolina.Price: $324.07, Change: $-5.75, Percent Change: -1.74%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $398, 17.1x our new 2027 EPS estimate, above AMGN's 10-year historical forward average of 14.1x, justified by its strengthening outlook. We raise our 2026 EPS view to $22.56 from $22.15 and our 2027 EPS to $23.23 from $22.83. AMGN delivered a strong Q1, showcasing significant positive momentum across its business. The company's six core growth drivers generated $5.6 billion in the quarter, growing 24% Y/Y. Standout performers included Repatha, with 34% Y/Y sales growth and the rare disease drug Uplinza, which saw sales surge 188% Y/Y. In terms of pipeline advancement, we continue to view the developments on Amgen's obesity treatment candidate, MariTide, as encouraging. AMGN announced new Phase III trials to explore less frequent dosing schedules (every eight or 12 weeks), a key potential differentiator, in our view. MariTide's potential for monthly or even less frequent (quarterly) dosing could be an important differentiator that would improve patient convenience and long-term adherence.
Health care stocks declined late Friday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.4%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 1.4%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 4.9%.Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said. Lilly shares rose 3.1%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.9%.
Health care stocks fell Friday afternoon with the NYSE Health Care Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 2.9%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 5.6%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.2%.
Amgen's (AMGN) posted in-line Q1 revenue, but EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said in a Friday research report.The brokerage said it sees favorable access dynamics for the company's Uplinza, which could become the first-line choice for appropriate patients. The company also announced the trials of the MariTide drug for obesity and type 2 diabetes.Morgan Stanley said it awaits further developments on Tavneos, for which FDA proposed to withdraw the approval, alleging ChemoCentryx manipulated the clinical data. Amgen may seek a hearing on this proposal, analysts said. While the company continues to believe in Tavneos' benefit-risk profile, the firm said the removal of the drug from its model would impact the price target.The brokerage said it reiterated its equalweight rating on the stock and boosted its price target to $332 per share from $326.Price: $329.27, Change: $-16.99, Percent Change: -4.91%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
Amgen (AMGN) reported Q1 adjusted earnings late Thursday of $5.15 per diluted share, up from $4.90 a year earlier.Analysts polled by FactSet expected $4.77.Revenue for the three months ended March 31 was $8.62 billion, up from $8.15 billion a year earlier.Analysts surveyed by FactSet expected $8.58 billion.For the full-year 2026, the company now expects adjusted EPS of $21.70 to $23.10 on revenue of $37.10 billion to $38.50 billion. Analysts expect EPS of $22.33 on revenue of $37.81 billion.
GUIDANCE: (AMGN) Amgen Expects 2026 Adjusted EPS Range $21.70-$23.10, vs. FactSet Est of $22.16
GUIDANCE: (AMGN) Amgen Expects 2026 Revenue Range $37.1B-$38.5B, vs. FactSet Est of $37.81B
Amgen (AMGN) has an average rating of overweight and mean price target of $357.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Amgen (AMGN) has an average rating of overweight and mean price target of $357.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $350.13, Change: $-0.88, Percent Change: -0.25%